Helixbind, Inc.

HelixBind develops a diagnostic platform for identifying bloodstream infections and sepsis that delivers results in approximately four hours, compared to the two to three days required for traditional blood culture tests. The platform provides faster and more accurate microbial identification to help clinicians select appropriate antimicrobial treatments and reduce the spread of antimicrobial resistance.